| Incidence of Relapse and Post-Kala-Azar Dermal Leishmaniasis in South Sudan (NCT05449717) | Epicentre | 2022-05-31 |
| A Clinical Study to Develop a Controlled Human Infection Model Using Leishmania Major-infected Sand Flies (NCT04512742) | University of York | 2021-10-16 |
| Safety, Tolerability and Pharmacokinetics (PK) Investigation of GSK3494245 in Healthy Participants (NCT04504435) | GlaxoSmithKline | 2020-09-29 |
| Mediterranean Visceral Leishmaniasis With Leishmania Infantum (NCT03784248) | Centre Hospitalier Universitaire de Nice | 2019-07-03 |
| Prevalence of HIV +ve Cases With AIDS Defining Opportunistic Infections Among ART Naive Patients Attending ART Centre (NCT03993093) | Singh, Ranjan Kumar, M.D. | 2019-06-01 |
| Safety, Tolerability and Pharmacokinetics (PKs) Investigation of GSK3186899 in Healthy Subjects (NCT03874234) | GlaxoSmithKline | 2019-04-30 |
| Defining Skin Immunity of a Bite of Key Insect Vectors in Humans (NCT03641339) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-09-05 |
| Topical Liposomal Amphotericin B Gel Treatment for Cutaneous Leishmaniasis (NCT02656797) | Soroka University Medical Center | 2018-01-30 |
| The Association of Miltefosine and Pentoxifylline to Treat Mucosal and Cutaneous Leishmaniasis: A Clinical Trial in Brazil (NCT02530697) | University of Brasilia | 2015-08-01 |
| Treatment of Leishmaniasis With Impavido® (Miltefosine): Higher-Weight Patient Registry (NCT02429505) | Knight Therapeutics (USA) Inc | 2015-07-01 |
| Fourth-generation Immucillin Derivative DI4G Associated Therapy in Cutaneous Leishmaniasis (NCT03294161) | Hospital Universitário Professor Edgard Santos | 2014-12-01 |
| Fractional CO2 Laser With Topical Pentostam Treatment for Cutaneous Leishmaniasis. (NCT03009422) | Tel-Aviv Sourasky Medical Center | 2014-11-01 |
| LEISH-F3 + GLA-SE and the LEISH-F3 + MPL-SE Vaccine (NCT01751048) | National Institute of Allergy and Infectious Diseases (NIAID) | 2013-03-01 |
| Phase 1 LEISH-F3 Vaccine Trial in Healthy Adult Volunteers (NCT01484548) | Access to Advanced Health Institute (AAHI) | 2012-01-01 |
| Intralesional Antimony for Bolivian Cutaneous Leishmaniasis (NCT01300975) | Fundacion Nacional de Dermatologia | 2011-01-01 |
| Clinical Trial of Miltefosine to Treat Mucosal Leishmaniasis (NCT01377974) | Brasilia University Hospital | 2009-07-01 |
| Mechanisms Relating to the Distinct in Vitro Susceptibility of Human Macrophages to L. Viannia Infection (NCT00401557) | Yale University | 2006-12-01 |
| Expression of Mif Alleles in Individuals With Leishmaniasis (NCT00401349) | Yale University | 2006-12-01 |
| Th1/Th2 Polarization and Linkage to L. Viannia Infection Outcomes (NCT00401297) | Yale University | 2006-12-01 |
| Miltefosine (Long Course) for Bolivian Mucosal Leishmaniasis (NCT00373568) | AB Foundation | 2005-04-01 |
| Use of Sodium Stibogluconate as a Treatment for Leishmaniasis (NCT00657618) | U.S. Army Medical Research and Development Command | 2004-10-01 |
| Miltefosine for Mucosal Leishmaniasis (NCT00373776) | AB Foundation | 2004-04-01 |
| Sodium Stibogluconate Treatment of Leishmaniasis (NCT00662012) | U.S. Army Medical Research and Development Command | 2002-06-01 |
| Diagnosis and Treatment of Leishmania Infections (NCT00344188) | National Institute of Allergy and Infectious Diseases (NIAID) | 2001-11-30 |
| Allopurinol, Glucantime, or Allopurinol/Glucantime for Cutaneous Leishmaniasis in Brazil (NCT00004755) | National Institute of Allergy and Infectious Diseases (NIAID) | 1995-09-01 |
| Clinical Investigation of Infections Due to Leishmanial Parasites (NCT00001169) | National Institute of Allergy and Infectious Diseases (NIAID) | 1979-12-01 |
| SCH708980 With and Without AmBisome for Visceral Leishmaniasis (NCT01437020) | National Institute of Allergy and Infectious Diseases (NIAID) | |